Healthcare IT Management

The report finds that the European and the US biotechnology industries both have around 2000 companies, but the US sector employs nearly twice as many people, spends around three times as much on research and development, has twice the number of employees involved in research and development, raises over twice as much venture capital, and has access to 10 times as much debt finance. It earns twice as much revenue.Despite the right-minded high-level political intentions to transform Europe into an innovation-intensive economic powerhouse, Europe's biotechnology project is in danger of foundering from the relative dearth of that most vital of fuels for innovation: money. There is a good deal of national government enthusiasm for biotechnology, apparent in a myriad of technology transfer initiatives, seed funding schemes, and taxation schemes encouraging bioscience and other hightechnology research and development.According to John Hodgson, Partner at Critical I - a specialist biotechnology consultancy